Voyager Therapeutics’ (VYGR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued to investors on Monday,Benzinga reports. The firm currently has a $30.00 price target on the stock.

VYGR has been the topic of several other reports. Citigroup started coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Wedbush reissued an “outperform” rating and issued a $9.00 target price (down from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. Cantor Fitzgerald started coverage on Voyager Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $5.73 target price on the stock. Finally, StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $15.72.

Voyager Therapeutics Stock Up 4.8 %

Shares of VYGR stock opened at $4.15 on Monday. The stock has a market cap of $226.70 million, a price-to-earnings ratio of 5.85 and a beta of 0.99. The business’s fifty day moving average is $5.11 and its 200 day moving average is $5.97. Voyager Therapeutics has a twelve month low of $3.80 and a twelve month high of $10.66.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new position in shares of Voyager Therapeutics in the fourth quarter worth about $29,000. Tower Research Capital LLC TRC raised its stake in shares of Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after buying an additional 3,077 shares during the period. Picton Mahoney Asset Management raised its stake in shares of Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after buying an additional 2,444 shares during the period. Oxford Asset Management LLP bought a new position in shares of Voyager Therapeutics in the fourth quarter worth about $60,000. Finally, Intech Investment Management LLC bought a new position in shares of Voyager Therapeutics in the third quarter worth about $74,000. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.